ECSP21081726A - Inhibidores de dihidroorotato deshidrogenasa - Google Patents

Inhibidores de dihidroorotato deshidrogenasa

Info

Publication number
ECSP21081726A
ECSP21081726A ECSENADI202181726A ECDI202181726A ECSP21081726A EC SP21081726 A ECSP21081726 A EC SP21081726A EC SENADI202181726 A ECSENADI202181726 A EC SENADI202181726A EC DI202181726 A ECDI202181726 A EC DI202181726A EC SP21081726 A ECSP21081726 A EC SP21081726A
Authority
EC
Ecuador
Prior art keywords
dehydrogenase inhibitors
dihydroorotate dehydrogenase
dihydroorotate
inhibitors
attached
Prior art date
Application number
ECSENADI202181726A
Other languages
English (en)
Inventor
Scott Kuduk
Aihua Wang
Zhuming Zhang
Lindsey Deratt
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of ECSP21081726A publication Critical patent/ECSP21081726A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se acompaña resumen
ECSENADI202181726A 2019-04-17 2021-11-16 Inhibidores de dihidroorotato deshidrogenasa ECSP21081726A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962835113P 2019-04-17 2019-04-17

Publications (1)

Publication Number Publication Date
ECSP21081726A true ECSP21081726A (es) 2021-12-30

Family

ID=70465152

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202181726A ECSP21081726A (es) 2019-04-17 2021-11-16 Inhibidores de dihidroorotato deshidrogenasa

Country Status (24)

Country Link
US (2) US11505536B2 (es)
EP (1) EP3956320B1 (es)
JP (2) JP7566776B2 (es)
KR (1) KR20220002964A (es)
CN (1) CN114174278B (es)
AR (1) AR118724A1 (es)
AU (1) AU2020259384A1 (es)
BR (1) BR112021020520A2 (es)
CA (1) CA3136791A1 (es)
CL (1) CL2021002681A1 (es)
CO (1) CO2021015264A2 (es)
CR (1) CR20210520A (es)
DO (1) DOP2021000211A (es)
EC (1) ECSP21081726A (es)
ES (1) ES2968809T3 (es)
IL (1) IL287268A (es)
MA (1) MA55716A (es)
MX (1) MX2021012706A (es)
PE (1) PE20220761A1 (es)
PH (1) PH12021552555A1 (es)
SG (1) SG11202111179RA (es)
TW (1) TW202104207A (es)
UY (1) UY38670A (es)
WO (1) WO2020212897A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005270A (es) * 2019-11-01 2022-06-09 Janssen Biotech Inc Derivados de quinolina y quinoxalina fluoradas como inhibidores de dihidroorotato deshidrogenasa (dhodh) para el tratamiento del cancer, enfermedades autoinmunes e inflamatorias.
TWI878414B (zh) 2019-12-19 2025-04-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
WO2022012548A1 (en) * 2020-07-14 2022-01-20 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Compounds as dhodh inhibitors
WO2022070068A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
WO2022074534A1 (en) * 2020-10-05 2022-04-14 Janssen Biotech, Inc. Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents
WO2022200615A1 (en) 2021-03-26 2022-09-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Pyrimidine biosynthesis inhibitor combination for use in treating viral infections
KR20240006638A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
KR20240006631A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
WO2023064880A1 (en) * 2021-10-13 2023-04-20 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
AR127621A1 (es) * 2021-11-09 2024-02-14 Vigil Neuroscience Inc Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso
JP2025540762A (ja) 2022-11-30 2025-12-16 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ阻害剤及びｂｃｌ－２阻害剤を含む組み合わせ
EP4626426A1 (en) 2022-11-30 2025-10-08 JANSSEN Pharmaceutica NV Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1726585A4 (en) * 2004-03-05 2009-07-15 Banyu Pharma Co Ltd DIARYLSUBSTITUTED FIVE-GLOSS HETEROCYCLUS DERIVAT
JP2007015952A (ja) * 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
WO2008091555A2 (en) * 2007-01-22 2008-07-31 Gtx, Inc. Nuclear receptor binding agents
DK3290407T3 (da) * 2013-10-18 2020-03-23 Celgene Quanticel Res Inc Bromodomæneinhibitorer
KR102209667B1 (ko) * 2014-09-19 2021-01-29 포르마 세라퓨틱스 인크. 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체
ES2788454T3 (es) 2014-12-18 2020-10-21 Takeda Pharmaceuticals Co Formas en estado sólido de pirrolidinonas heteroaromáticas condensadas
WO2018077944A2 (en) 2016-10-27 2018-05-03 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
WO2018154088A1 (en) 2017-02-24 2018-08-30 Merck Patent Gmbh 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors
WO2019191030A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite
TW202043208A (zh) 2019-01-11 2020-12-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
KR20210125519A (ko) 2019-02-07 2021-10-18 얀센 바이오테크 인코포레이티드 다이하이드로오로테이트 탈수소효소 억제제

Also Published As

Publication number Publication date
US20220298137A1 (en) 2022-09-22
BR112021020520A2 (pt) 2021-12-07
CA3136791A1 (en) 2020-10-22
ES2968809T3 (es) 2024-05-14
SG11202111179RA (en) 2021-11-29
PE20220761A1 (es) 2022-05-16
PH12021552555A1 (en) 2022-06-20
US11753393B2 (en) 2023-09-12
CL2021002681A1 (es) 2022-05-27
TW202104207A (zh) 2021-02-01
MA55716A (fr) 2022-02-23
JP2025000916A (ja) 2025-01-07
AR118724A1 (es) 2021-10-27
CN114174278B (zh) 2024-08-23
JP7566776B2 (ja) 2024-10-15
AU2020259384A1 (en) 2021-11-11
UY38670A (es) 2020-10-30
IL287268A (en) 2021-12-01
CN114174278A (zh) 2022-03-11
US11505536B2 (en) 2022-11-22
EP3956320A1 (en) 2022-02-23
JP2022530203A (ja) 2022-06-28
US20200331881A1 (en) 2020-10-22
KR20220002964A (ko) 2022-01-07
CR20210520A (es) 2021-12-20
WO2020212897A1 (en) 2020-10-22
MX2021012706A (es) 2022-01-31
DOP2021000211A (es) 2022-05-31
CO2021015264A2 (es) 2021-11-19
EP3956320B1 (en) 2023-11-29

Similar Documents

Publication Publication Date Title
IL289534A (en) Parp1 inhibitors
EP4069212A4 (en) HIF-2 ALPHA INHIBITORS
MA55716A (fr) Inhibiteurs de dihydroorotate déshydrogénase
IL287787A (en) Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
IL287795A (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
MX2022007527A (es) Inhibidores de proteinas kras mutantes.
EP4262803A4 (en) Tetrahydropyridopyrimidine pan-kras inhibitors
CL2019000992A1 (es) Conjugados de pirrolobenzodiazepina.
IL288996A (en) Aminopyrimidine amide autophagy inhibitors and methods of use thereof
MA54695A (fr) Inhibiteurs de dihydroorotate déshydrogénase
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
JOP20200276A1 (ar) مثبطات أحادي أسيل جليسرول ليباز (magl)
EP4434979A4 (en) KIF18A INHIBITOR
IL287751A (en) Kcnt1 inhibitors and methods of use
IL287768A (en) Kcnt1 inhibitors and methods of use
EP3801500A4 (en) Inhibitors of sarm1
IL277778B (en) Bcl6 inhibitors
JOP20200081A1 (ar) أملاح من مشتقات بيرولوتريازين مفيدة بوصفها مثبطات لـ tam
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
JOP20210036A1 (ar) مثبطات او- جليكوبروتين-2-أسيتاميدو-2-ديوكسي-3-دي-جلوكوبيرانوسيداز
IL281742A (en) Novel compounds as nadph oxidase inhibitors
EP4333821A4 (en) SARS-COV-2 INHIBITORS
IL292860A (en) Allosteric egfr inhibitors and methods of use thereof
IL285546A (en) Compounds and methods for reducing kcnt1 expression
EP4168398A4 (en) TYK-2 INHIBITOR